Can Vaccines Work Less Effectively on Cosentyx?
Yes, Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, reduces immune response to certain vaccines. Clinical data show it impairs effectiveness of live vaccines and weakens antibody production from non-live ones.[1][2]
Which Vaccines Are Affected?
Live vaccines (e.g., MMR, varicella, oral polio, yellow fever) are contraindicated during Cosentyx treatment due to infection risk from suppressed immunity. Non-live vaccines (e.g., influenza, pneumococcal, Tdap, COVID-19) produce lower antibody titers—often 20-50% reduced compared to placebo. For example, secukinumab users had 39% fewer responders to influenza vaccine strains in trials.[1][3]
How Long Do Effects Last?
Vaccine response remains impaired for at least 6-12 months after stopping Cosentyx, based on immunogenicity studies. Providers recommend vaccinating 4-6 weeks before starting therapy or delaying until after discontinuation.[2][4]
What Do Guidelines Say?
FDA and EMA labels advise avoiding live vaccines. ACIP and EULAR recommend prioritizing non-live vaccines pre-treatment. Post-treatment boosters may be needed if titers are low.[1][5]
Real-World Patient Experiences
Patients report breakthrough infections despite vaccination (e.g., flu, shingles) while on Cosentyx. Rheumatology forums note frequent titer checks and revaccinations.[6]
How Does This Compare to Other Biologics?
| Drug | Vaccine Impact | Live Vaccine OK? |
|------|----------------|------------------|
| Cosentyx (IL-17) | Moderate antibody reduction | No |
| Humira (TNF) | Similar, slightly less | No |
| Stelara (IL-12/23) | Milder | No |
| Skyrizi (IL-23) | Least impact | No |
TNF inhibitors like Humira show comparable or greater suppression; IL-23 drugs like Skyrizi have minimal effects.[3][7]
Doctor Recommendations
Test antibody levels 4 weeks post-vaccination. Update routine shots (shingles, pneumococcal) before starting. No increased COVID-19 vaccine issues beyond general reduction.[4][8]
Sources
[1]: Cosentyx Prescribing Information (FDA)
[2]: EMA Cosentyx Summary (2023)
[3]: Bagci et al., J Am Acad Dermatol (2021) - Vaccine responses in IL-17 inhibitors
[4]: EULAR Recommendations for Vaccination in Rheumatic Diseases (2019)
[5]: CDC ACIP Adult Immunization Schedule (2024)
[6]: Patient reports from ClinicalTrials.gov and PubMed case series
[7]: Schreiber et al., Rheumatology (2022) - Biologic vaccine comparisons
[8]: CDC COVID-19 Vaccine Guidance for Immunocompromised (2024)